CANbridge Pharmaceuticals Inc. (HKG:1228)

Market Cap	1.20B +766.8%
Revenue (ttm)	55.62M -41.3%
Net Income	16.49M
EPS	0.03
Shares Out	595.44M
PE Ratio	60.21
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	539,000
Open	2.010
Previous Close	2.010
Day's Range	1.980 - 2.080
52-Week Range	0.520 - 3.500
Beta	-0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About CANbridge Pharmaceuticals

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 41
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1228

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error